top of page
Developing drugs for the treatment of


About Us

Haoma Medica is a UK based biotech company that focuses on treatments for Osteoporosis and Osteopenia as well as blood clotting management. The Osteoporosis & Osteopenia drug referred to as NaQuinate and commercially as Osteopura, is a novel class of compound that has a new mechanism of action compared with existing treatments and is designed for low dose oral administration. The chemical compound, NaQuinate, occurs naturally within the body and appears to preserve both bone mass and bone architecture and thus the safety profile of this therapeutic approach has significant potential for the long-term treatment of the serious condition of Osteoporosis.


The active substance in Osteopura is present in all people, but only in very small amounts. Osteopura boosts the levels of this naturally occurring compound to preserve bone integrity. Haoma Medica started with the platform of “working with nature and not against it”.   


A novel therapeutic for the treatment of Osteoporosis

Anticipated Strengths of NaQuinate

  • Novel class of compound

  • Unique mechanism of action

  • Product naturally occuring in the body

  • Small molecule

  • Low toxicity

  • Low dosage

  • Ability to improve bone quality not just quantity

  • Non gender specific 

  • Administered orally

  • ‘Quick On, Quick Off'

  • Inexpensive to manufacture

  • Beneficial additional effects

Inhibits bone loss in a pharmaceutical industry “Gold Standard” animal model of postmenopausal osteoporosis. The market is ready for a novel treatment with a new mechanism of action in the management of patients at risk of fracture; one that addresses the unmet need for a therapy with better efficacy in the treatment and prevention of long bone fractures, and one that provides anabolic characteristics but with a better safety profile. We believe NaQuinate and Osteopura can meet these requirements.


Patent Update

Haoma Medica has three patents, two have been granted and one is pending grant. They cover the following countries: UK, US, Canada, Australia, Japan, Korea, Hong Kong, Russia, India, China, Brazil, Isreal and the European zone


Our current strategy within the early clinical development phase is focused on identifying and understanding more about NaQuinate’s unique mechanism of action compared with all current treatments and its ability to improve bone quality not just quantity.

Phase I

We have completed our first in human study. This was a single and multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of varying doses of NaQuinate in healthy subjects. A full press release is available on our Press Release page.

Phase Ib

Phase Ib Study in Healthy Post-Menopausal Women has been initiated. It is designed as a randomised, double-blind, placebo-controlled parallel group study to investigate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of NaQ in healthy post-menopausal women with low bone mineral density. The objective is to study the safety and tolerability of NaQ with longer term treatment (28 days) in our target subject demographic prior to a 2-year treatment patient study in post-menopausal women with osteoporosis. In addition, the study will help to confirm a bone pharmacodynamic effect in humans.

Phase II

Our proposed Phase II study combines the objectives of a Phase IIa proof of concept study in patients with osteoporosis and osteopenia and a Phase IIb dose ranging study to help select doses for Phase III pivotal registration trials. More advanced technologies such as quantitative computed tomography (QCT) and High Resolution peripheral QCT will be used to evaluate the effects of treatment on different bone compartments and at a level that can evaluate drug treatment effects on bone geometry and microarchitecture (for e.g. cortical thickness and cortical porosity). Estimates of bone strength in patients will also be assessed using finite element analysis. We expect to initiate the Phase II program for Osteoporosis later in 2020.



LONDON, Sep. 16, 2022 /PRNewswire/Haoma Medica Announces Late-Breaking Science Results for Naquinate, as a New Way to Support Bone Health and Healthy Aging, at the ASBMR 2022 Annual Meeting

Haoma Medica announced at a presentation made at the 2022 American Society for Bone and Mineral Research:

Dr Stephen Hodges, Lead Investigator presented 'A vitamin K catabolite regulates Wnt 16-mediated B-catenin activation leading to increased osteoblast proliferation, with enhanced expression of osteocalcin and osteoprotegrin'.

Previous studies have shown Naquinate, a vitamin K catabolite, to protect against reduction in bone quality and quantity occurring in response to ovariectomy in rat and mouse models. In the data presented today using primary human femoral osteoblasts, Naquinate increased osteoblast proliferation after 3 days compared to control cultures. Cell extracts revealed enhanced expression of osteocalcin, osteoprotegrin and Wnt16 with translocation of B-catenin to the cell nucleus. In a parallel study using liver microsomes in the presence/absence of vitamin K, Naquinate did not affect gamma-carboxylation of osteocalcin.

'These results indicate a dual action for Naquinate on both bone resorption and bone formation pathways and shows that Naquinate does not work through the often-proposed classical bone actions of vitamin K. Naquinate itself appears to have a different and unique biological activity compared to vitamin K. Wnt16 is more active in cortical and Naquinate may be involved in regulating the cortical bone thickness and porosity,' said Dr Stephen Hodges, presenting author.


LONDON, Haoma Medica announced today the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis. 

''We are delighted that the first-in-human study has completed its last dosing. There were no significant safety or tolerability concerns up to the highest doses tested which underlines our expectation that NaQuinate is safe and well tolerated,'' said Dr Cenk Oguz, Haoma Medica's Chief Medical Officer.

'Our pre-clinical research has revealed an exciting feature of NaQuinate where it appears to have the capacity to work in harmony with the body's natural response to weight bearing exercise to synergistically enhance bone formation when and where required – now that would be a 'smart' drug,' said Dr Steve Deacon, Haoma Medica's CEO.


'Together with the safety data from this first-in-human study, this supports the potential that NaQuinate treatment could provide a safe, novel and smart therapeutic approach to bone disorders like osteoporosis and better maintain healthy skeletal aging.


Fund Raising

Seed Raise

Haoma Medica is looking to raise a Seed round for it's nutriceutical subsidiary, The PuraLife Company. 

Osteopura+ is the flagship nutraceutical product range- new and unique combination of ingredients carefully formulated by Dr Cenk Oguz, and bone health scientists, to build better bones before it is too late. We provide a range of products aimed at teenagers to over 65+

ASBMR, September 2022 Annual Meeting

Poster Presentation
Haoma Medica Announces Late-Breaking Science Results for Naquinate, as a New Way to Support Bone Health and Healthy Aging, at the ASBMR 2022 Annual Meeting

ECTS Digital Congress 2021- May 2021

Presentation Title 
NaQuinate selectively synergises with in vivo mechanical loading stimuli to enhance cortical bone mass and architectural modifications

Poster Tour Oral Presentation
Basic Science session 
Poster presentation: P016
8th May, 11:30-12:00 CET

Oral Presentation
ECTS@Home session 
Pre-clinical Mouse Models in Musculoskeletal
Research session
20th May, 14:00-16:00 CET
Presentation ECTS21-0177

bottom of page